Theracryf Plc Appoints New Nominated Adviser and Joint Broker
The clinical stage drug development company has appointed a new nominated adviser and joint broker.
The clinical stage drug development company has appointed a new nominated adviser and joint broker.
The clinical stage therapeutics company is hosting an investor presentation on its Ox-1 addiction programme.
The clinical-stage drug developer has extended its cash runway and sharpened focus on its orexin-1 antagonist program for addiction treatment, while maintaining progress in other areas.
The clinical-stage therapeutics company announces the release of its full year results and a presentation on its Ox-1 addiction programme.
The healthcare company has announced a transfer of a 19.67% shareholding from Tracarta Limited to its 51% owned subsidiary, Northern Standard Limited.
The healthcare company has announced a change in one of its director's shareholdings.
The healthcare company has announced changes to its major shareholdings.
The clinical stage drug development company has signed an agreement with contract research organisation Pharmaron to progress development of its Orexin-1 addiction programme.
The clinical-stage drug development company announces a new non-executive director appointment and grants of options to employees and management.
The clinical stage therapeutics company is hosting an investor webinar to discuss its plans for its Ox-1 addiction and SFX-01 glioblastoma programmes.